GSK plc stock (GB0009252882): asthma approval and oncology push keep the pharma story moving

GSK has secured a fresh US approval for its asthma drug Nucala in children and is doubling down on oncology, while investors digest its latest quarterly results and vaccine performance. What is driving the British pharma group’s stock story for US-focused investors?

GSK plc has stayed in the headlines in recent weeks with a mix of regulatory, pipeline and earnings news. The British pharmaceutical group won a new US approval for its respiratory drug Nucala in younger children, advanced its oncology ambitions with the expected acquisition of an autoimmune and oncology specialist, and reported higher first-quarter revenue, according to company statements and filings published in April and May 2026. These developments add new layers to the investment narrative around the former GlaxoSmithKline as it seeks to grow beyond its traditional respiratory and vaccine franchises.

On 05/13/2026, the US Food and Drug Administration (FDA) approved an expanded indication for GSK’s monoclonal antibody Nucala (mepolizumab) as an add-on treatment for severe eosinophilic asthma in children aged 2 to 5 years, according to a company press release cited by specialist media on that date. The drug was already used in older patients, and the extended label could help GSK defend and grow its respiratory revenues in a competitive biologics market, as reported by Reuters as of 05/13/2026. Management has repeatedly highlighted respiratory and specialty medicines as key growth platforms in recent quarterly presentations.

Earlier in the quarter, on 04/24/2026, GSK reported its first-quarter 2026 results, stating that group turnover grew year over year, with vaccines and specialty medicines contributing the largest share of sales, according to the company’s Q1 2026 earnings release and slide deck published on the same day. The group also said it continued to invest heavily in its pipeline, particularly in respiratory, HIV, vaccines and oncology, while maintaining its full-year 2026 guidance, as reflected in the slides and commentary provided to investors on 04/24/2026, according to GSK investor information as of 04/24/2026.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GSK
• Sector/industry: Pharmaceuticals, vaccines and consumer health legacy
• Headquarters/country: London, United Kingdom
• Core markets: Europe, United States and other international markets
• Key revenue drivers: Vaccines, HIV medicines, respiratory and specialty drugs
• Home exchange/listing venue: London Stock Exchange (ticker: GSK); secondary listing on NYSE (ticker: GSK)
• Trading currency: GBP in London, USD on NYSE

GSK plc: core business model

GSK plc is a global biopharmaceutical group focusing on prescription medicines and vaccines after separating its consumer health activities into a standalone company in 2022. The company develops, manufactures and markets medications in therapeutic areas such as infectious diseases, HIV, respiratory and immuno-inflammation, alongside its vaccine portfolio. In its Q1 2026 materials, GSK again positioned itself as a research-driven firm with a pipeline centered on vaccines and specialty medicines that aim to modify disease and prevent illness, according to company documents released on 04/24/2026.

The company’s business model combines high-volume vaccine franchises, chronic treatments such as HIV therapies, and specialty medicines including biologics for asthma and autoimmune conditions. These products are often protected by patents, which can support pricing power and margins during the exclusivity period. However, when key drugs face generic or biosimilar competition, revenue can decline, which is why GSK emphasizes constant pipeline renewal in investor communications. The group’s R&D strategy includes internal research and targeted business development deals to acquire or in-license promising candidates.

GSK also runs a broad vaccines operation, with products targeting diseases ranging from shingles and influenza to respiratory syncytial virus (RSV). In 2023 and 2024, the launch of the RSV vaccine Arexvy for older adults was highlighted by the company as a major growth driver, and management has continued to stress RSV as a strategic focus in its more recent updates, according to investor day and earnings presentations referenced in the Q1 2026 documentation dated 04/24/2026. Vaccines can provide recurring revenue patterns due to seasonal or booster dosing, but they also require significant manufacturing capacity and quality control.

In the HIV segment, which GSK manages primarily through its ViiV Healthcare joint venture, the company markets a range of therapies including integrase inhibitors and long-acting injectable regimens. These products target both treatment-naïve and treatment-experienced patients, and the company has set out a strategy to move towards longer-acting formulations that could improve adherence, according to prior pipeline discussions summarized again in GSK’s Q1 2026 materials. This segment is important for cash flow but faces competition and price pressure in both the US and global markets.

Main revenue and product drivers for GSK plc

According to GSK’s Q1 2026 earnings release published on 04/24/2026, group turnover for the quarter rose versus the prior-year period, driven mainly by vaccines and specialty medicines. Within vaccines, shingles vaccine Shingrix remained a significant contributor, particularly in the United States and other developed markets where adult vaccination programs are more established. Management indicated that Shingrix uptake continues in both existing and emerging markets, while RSV vaccine Arexvy is being rolled out across multiple geographies, according to the same 04/24/2026 investor materials.

In specialty medicines, respiratory and immunology drugs such as Nucala and Trelegy play an important role in revenue generation. The recent FDA approval of Nucala for younger children with severe eosinophilic asthma could open a new patient segment and extend the product’s lifecycle in the US market, according to Reuters as of 05/13/2026. While the pediatric population is smaller than the adult asthma market, the decision reinforces Nucala’s clinical profile and may support demand in severe disease, where treatment options can be limited and biologics often command premium pricing.

The HIV franchise also remains a core revenue driver. In the Q1 2026 update, GSK pointed to ongoing sales of its integrase-based regimens and highlighted the continued rollout of long-acting injectable treatments for appropriate patients, according to the 04/24/2026 earnings statement. These therapies are primarily marketed in high-income countries including the United States, which is a key market for HIV treatment revenues. However, the broader HIV segment faces rising competitive intensity, with multiple large pharmaceutical firms targeting similar pathways and focusing on convenience and resistance profiles.

Another important area is general medicines, which includes a mix of respiratory products, inhalers and other established drugs. While these medicines can generate steady cash flow, GSK has signaled that it sees the highest growth potential in vaccines and specialty medicines, which tend to offer higher margins and more differentiated clinical profiles, according to its Q1 2026 strategic commentary. Over time, the company aims to shift its portfolio mix further toward these high-value segments, which may influence capital allocation and marketing priorities.

The company’s quarterly results also underscored the importance of geographic mix. The United States remains one of GSK’s largest markets by revenue, especially for Shingrix, HIV medicines and specialty respiratory drugs, as highlighted in previous annual reports and reiterated during the Q1 2026 results presentation. This exposure to the US healthcare system can be a double-edged sword: it offers pricing and volume opportunities but also brings regulatory and reimbursement scrutiny from payers and policymakers.

Why GSK plc matters for US investors

For US investors, GSK plc is accessible both through its American depositary shares on the New York Stock Exchange and via international brokerage platforms that provide access to the London listing. The company is a significant player in key US therapeutic markets such as HIV, respiratory disease and adult vaccines, and its revenue and profit trends are influenced by US prescription volumes, pricing dynamics and reimbursement decisions. This makes the stock relevant not only to investors seeking exposure to European pharma but also to those focused on the US healthcare ecosystem.

US policy debates around drug pricing, Medicare negotiations and vaccine funding can affect GSK’s financial outlook. For example, any changes to US rules around reimbursement for shingles vaccines or RSV immunizations could influence uptake and revenue trajectories for Shingrix and Arexvy. GSK’s HIV portfolio is also exposed to US insurance coverage decisions and competition from other branded and generic therapies. Investors monitoring the stock often consider these policy and competitive factors alongside company-specific news, such as clinical trial results, approvals like the recent Nucala pediatric indication, and quarterly earnings updates.

Additionally, GSK’s R&D collaborations and potential business development deals with US-based biotech companies are watched closely by the market. The company has a history of partnering with smaller innovators to access cutting-edge science, particularly in oncology and immunology. Such collaborations can add pipeline assets and technology platforms, but they also bring integration and execution risks. For US investors who follow the biotech and pharma space, GSK represents a large, diversified player whose fortunes are tied closely to both European and US regulatory and commercial environments.

Conclusion

GSK plc’s recent news flow, including the expanded FDA approval for Nucala in young children and the first-quarter 2026 results, illustrates how the group is leaning on vaccines and specialty medicines to drive growth while managing competition in mature areas like HIV and respiratory. The company’s strong presence in the United States means that US healthcare policies, reimbursement trends and clinical guidelines can materially influence its revenues. At the same time, GSK’s strategy emphasizes pipeline expansion and targeted deals to sustain its portfolio, which may create opportunities but also adds execution risk. For investors, the stock reflects a large-cap pharmaceutical profile with a notable focus on vaccines and specialty treatments, supported by global diversification and a dual listing in London and New York.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.